Cibus, Inc.
CBUSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. With a market capitalization of $150.6M, it sits in micro-cap territory. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients.
Market Cap
$150.6M
Beta
1.65
P/E (TTM)
—
P/E (Fwd)
-2.95
EPS (TTM)
$-1.87
EPS (Fwd)
$-0.63
ROE
-190.1%
ROA
-11.2%
Cash
$30.3M
Total Debt
$276.2M
Free CF
-$52.7M
52W Change
8.1%
Annual Financials
Cash vs Debt
Where CBUS stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, CBUS finished 23.20% above its 150-day moving average ($1.94) and 32.04% above its 200-day moving average ($1.81). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CBUS overbought or oversold?
At the July 15, 2026 close, CBUS's RSI(14) was 90.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cibus, Inc. carries $276.2M in total debt against $30.3M in cash reserves — debt is roughly 9.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$52.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -190.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $157K (2022) to $3.6M (2025), reflecting a 2218% increase over the period.
With a beta above 1.5, CBUS tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cibus, Inc.'s trajectory.